Coloplast Future Growth

Future criteria checks 2/6

Coloplast wird ein jährliches Wachstum der Erträge und Einnahmen um 11.3% bzw. 8.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 10.8% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 35.6% betragen.

Key information

12.4%

Earnings growth rate

12.0%

EPS growth rate

Medical Equipment earnings growth	18.7%
Revenue growth rate	8.4%
Future return on equity	34.2%
Analyst coverage	Good
Last updated	03 Apr 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Apr 13

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Mar 29

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 12

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Jan 12

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Dec 28

Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All

Nov 25

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Oct 31

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Oct 02

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

Sep 16

Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?

Aug 02

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Jul 01

Does Coloplast (CPH:COLO B) Deserve A Spot On Your Watchlist?

Jun 16

Coloplast A/S (CPH:COLO B) Shares Could Be 34% Above Their Intrinsic Value Estimate

May 02

Would Coloplast A/S (CPH:COLO B) Be Valuable To Income Investors?

Apr 11

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Mar 29

Will Weakness in Coloplast A/S' (CPH:COLO B) Stock Prove Temporary Given Strong Fundamentals?

Mar 16

I Built A List Of Growing Companies And Coloplast (CPH:COLO B) Made The Cut

Mar 02

Did You Participate In Any Of Coloplast's (CPH:COLO B) Fantastic 123% Return ?

Feb 17

What Percentage Of Coloplast A/S (CPH:COLO B) Shares Do Insiders Own?

Feb 03

Earnings and Revenue Growth Forecasts

CPSE:COLO B - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2026	32,087	7,048	6,767	8,329	17
9/30/2025	29,592	6,213	6,006	7,439	19
9/30/2024	27,223	5,326	5,174	5,381	19
12/31/2023	25,001	4,868	4,285	5,527	N/A
9/30/2023	24,500	4,783	2,985	4,226	N/A
6/30/2023	24,333	4,784	3,226	4,485	N/A
3/31/2023	24,074	4,801	3,663	4,894	N/A
12/31/2022	23,515	4,626	3,246	4,455	N/A
9/30/2022	22,579	4,706	3,964	5,099	N/A
6/30/2022	21,620	4,781	3,894	4,913	N/A
3/31/2022	20,606	4,746	3,735	4,712	N/A
12/31/2021	19,857	4,896	4,272	5,209	N/A
9/30/2021	19,426	4,825	3,324	5,290	N/A
6/30/2021	18,916	4,561	3,102	5,023	N/A
3/31/2021	18,500	4,304	3,162	5,077	N/A
12/31/2020	18,570	4,241	3,003	4,941	N/A
9/30/2020	18,544	4,197	3,828	4,759	N/A
6/30/2020	18,572	3,949	3,876	4,842	N/A
3/31/2020	18,752	4,020	3,872	4,764	N/A
12/31/2019	18,330	3,974	3,833	4,615	N/A
9/30/2019	17,939	3,873	3,667	4,357	N/A
6/30/2019	17,555	4,119	3,599	4,161	N/A
3/31/2019	17,181	3,999	3,562	4,177	N/A
12/31/2018	16,815	3,896	3,522	4,126	N/A
9/30/2018	16,449	3,845	3,692	4,361	N/A
6/30/2018	16,195	3,816	3,587	4,370	N/A
3/31/2018	15,882	3,778	3,361	4,111	N/A
12/31/2017	15,728	3,791	3,235	4,004	N/A
9/30/2017	15,528	3,797	N/A	3,251	N/A
6/30/2017	15,287	3,211	N/A	2,994	N/A
3/31/2017	15,061	3,279	N/A	2,492	N/A
12/31/2016	14,780	3,264	N/A	2,653	N/A
9/30/2016	14,681	3,143	N/A	3,028	N/A
6/30/2016	14,563	1,297	N/A	3,081	N/A
3/31/2016	14,417	1,028	N/A	3,568	N/A
12/31/2015	14,264	927	N/A	3,320	N/A
9/30/2015	13,909	899	N/A	3,337	N/A
6/30/2015	13,502	3,162	N/A	3,119	N/A
3/31/2015	13,096	3,241	N/A	3,015	N/A
12/31/2014	12,666	2,407	N/A	3,193	N/A
9/30/2014	12,428	2,390	N/A	3,149	N/A
6/30/2014	12,184	2,298	N/A	3,177	N/A
3/31/2014	12,008	2,220	N/A	3,074	N/A
12/31/2013	11,833	2,874	N/A	3,270	N/A
9/30/2013	11,635	2,711	N/A	3,136	N/A
6/30/2013	11,514	2,570	N/A	2,912	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: COLO BDas prognostizierte Gewinnwachstum (11.3% pro Jahr) liegt über der Sparquote (0.7%).

Ertrag vs. Markt: COLO BDie Erträge des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Danish (12.6% pro Jahr).

Hohe Wachstumserträge: COLO BDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: COLO BDie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Danish (10.7% pro Jahr).

Hohe Wachstumseinnahmen: COLO BDie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: COLO BDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (35.6%)

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Coloplast Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Recent updates

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Third quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Contraline Names Yelena Tropsha as CTO

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021